Long-Term Persistence of Subfoveal Fluid Following Ocriplasmin-Treatment of an FTMH

Klin Monbl Augenheilkd 2017; 234(04): 524-526
DOI: 10.1055/s-0043-100559

Der interessante Fall

Georg Thieme Verlag KG Stuttgart · New York

Langfristige Persistenz subfovealer Flüssigkeit nach Ocriplasminbehandlung eines Makulaforamens

Autor*innen

S. Tschuppert

¹Department of Retinology, Klinik Pallas, Olten/Switzerland (Director: Prof. Dr. Heinrich Gerding)
H. Gerding

¹Department of Retinology, Klinik Pallas, Olten/Switzerland (Director: Prof. Dr. Heinrich Gerding)

²Department of Ophthalmology, University of Münster (Director: Prof. Dr. N. Eter)

References
1 Syed YY, Dhillon S. Ocriplasmin: A review of its use in patients with symptomatic vitreoumacular adhesion. Drugs 2013; 73: 1617-1625
2 Stalmans P, Benz MS, Gandorfer A. et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012; 367: 606-615
3 Tschuppert S, Gerding H. Transient subfoveal fluid and visual loss after ocriplasmin. Klin Monatsbl Augenheilkd 2016; 233: 453-455
4 Reiss B, Smithen L, Mansour S. Transient vision loss after ocriplasmin injection. Retina 2015; 35: 1107-1110
5 Singh RP, Li A, Bedi R. et al. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome. Br J Ophthalmol 2014; 98: 356-360
6 Margo JA, Schocket LS, Klima K. et al. Persistent retinal changes after intravitreal ocriplasmin. Retin Cases Brief Rep 2016; 10: 48-51
7 Dugel PU, Regillo C, Eliott D. Characterization of anatomic and visual function outcomes in patients with full-thickness macular hole in ocriplasmin phase 3 trials. Am J Ophthalmol 2015; 160: 94-99.e1